Direct Oral Anticoagulant Inhibitors: Mode of Action, Clinical Aspects
- 30 December 2025
- book chapter
- Published by Springer Nature
- p. 99-121
Abstract
This chapter provides a comprehensive overview of direct oral anticoagulants (DOACs), focusing on their mechanisms of action, clinical utility, and practical considerations in anticoagulation management. DOACs have revolutionised anticoagulation by selectively targeting thrombin and activated factor X (FXa), offering improved safety, predictable pharmacokinetics, and reduced need for monitoring. The chapter covers their indications, contraindications, dosing, perioperative management, reversal, and use in special populations, including those with renal or hepatic impairment, cancer-associated thrombosis, and extreme body weights. It provides clinicians with practical guidance for the effective application of DOACs in various clinical settings.Keywords
This publication has 79 references indexed in Scilit:
- Perioperative Management of Patients Taking Direct Oral AnticoagulantsJAMA, 2024
- Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of ExperienceDrugs & Aging, 2024
- Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopeniaJournal of Thrombosis and Thrombolysis, 2022
- Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysisJournal of Thrombosis and Thrombolysis, 2021
- Direct oral anticoagulants for unusual‐site venous thromboembolismResearch and Practice in Thrombosis and Haemostasis, 2021
- Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral AnticoagulantJAMA Internal Medicine, 2019
- Andexanet Alfa: First Global ApprovalDrugs, 2018
- Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High CreatinineJAMA Cardiology, 2016
- Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agentsJournal of Thrombosis and Thrombolysis, 2015
- Atrial fibrillation and obesity—results of a meta-analysisAmerican Heart Journal, 2008